Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron R Hansen

Showing results (151-160 of 159) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 159 results.
Journal for Immunotherapy of Cancer|March 17, 2023
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, et al.
Genome Medicine|October 27, 2016
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trialTracy L Stockley, Amit M Oza, Hal K Berman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2021
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update ConsortiumSilke Gillessen, Nicolas Sauvé, Laurence Collette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2026
International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROREmily Alger, Olalekan Lee Aiyegbusi, Amylou C Dueck, et al.
Journal for Immunotherapy of Cancer|March 15, 2019
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)Derek L Clouthier, Scott C Lien, S Y Cindy Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2024
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update ConsortiumEmanuel Bührer, David D'Haese, Gedske Daugaard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2021
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update ConsortiumJörg Beyer, Laurence Collette, Nicolas Sauvé, et al.
JAMA Network Open|October 28, 2020
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene AberrationsSabine Schmid, Aurelius Omlin, Celestia Higano, et al.
Journal of Personalized Medicine|November 27, 2021
Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation StudyZulfan Zazuli, Corine de Jong, Wei Xu, et al.
Pageof 16

Showing results (151-160 of 159) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 159 results.
Journal for Immunotherapy of Cancer|March 17, 2023
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, et al.
Genome Medicine|October 27, 2016
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trialTracy L Stockley, Amit M Oza, Hal K Berman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2021
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update ConsortiumSilke Gillessen, Nicolas Sauvé, Laurence Collette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2026
International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROREmily Alger, Olalekan Lee Aiyegbusi, Amylou C Dueck, et al.
Journal for Immunotherapy of Cancer|March 15, 2019
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)Derek L Clouthier, Scott C Lien, S Y Cindy Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2024
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update ConsortiumEmanuel Bührer, David D'Haese, Gedske Daugaard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2021
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update ConsortiumJörg Beyer, Laurence Collette, Nicolas Sauvé, et al.
JAMA Network Open|October 28, 2020
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene AberrationsSabine Schmid, Aurelius Omlin, Celestia Higano, et al.
Journal of Personalized Medicine|November 27, 2021
Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation StudyZulfan Zazuli, Corine de Jong, Wei Xu, et al.
Pageof 16